Biopharma venture capital fundraising declined from $8.1 billion in the first quarter of 2024 to $6.5 billion in the first ...

In light of President Donald Trump’s impending pharma tariffs, several big companies have made massive manufacturing ...

Twenty attorneys general allege that the recent workforce reduction at the Department of Health and Human Services is ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

The biotech’s Huntingtin-targeting molecule lowered blood levels of the protein and elicited functional improvements in ...

Bristol Myers Squibb has made significant cuts to its workforce since last year as part of a strategic reorganization aimed ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

The FDA’s user free programs account for just under half of the agency’s budget—money that could be imperiled by the recent ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...